Further analyses using cells from more osteosarcomas will be required to determine the feasibility of predicting responsiveness of individual tumors to BH3-mimetics through measuring expression levels of BCL-2 family members like MCL-1 and PUMA. The gene discussed is BCL2; the disease is osteosarcoma.